The Payer Analysis announcement that it was being performed was put out by IPIX. If I remember correctly, it was in a filing, most likely the end of year filing.

I hope now IPIX gets a good partner for OM. I believe they could do it alone but since OM is the smallest revenue generator of all of B's potential applications, let's get hooded up with a good BP that will be able to move the ball forward much, much quicker than IPIX alone. Don't lose sight of the forest for the trees.

The major benefit from the OM application IMO is that once B is approved for it follow on applications for B should go much quicker and smoother.

IBD will absolutely dwarf OM potential and the anti inflammatory applications, not to mention the broad spectrum antiviral possibilities, will rank right up there w/ IBD. We don't need OM to be a home run, we just need it like a good lead off batter to set up the heavy hitters coming up right behind it.